Status:
COMPLETED
A Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668
Lead Sponsor:
Genzyme, a Sanofi Company
Conditions:
Progressive Multiple Sclerosis
Eligibility:
All Genders
18-66 years
Brief Summary
Primary Objective: To assess the long-term safety of GZ402668 in patients with multiple sclerosis (MS) who received prior treatment during the TDU13475 or TDU14981 studies. Secondary Objectives: To...
Detailed Description
The total study duration for a patient is approximately 47 months. There is no administration of GZ402668 in the LTS14120 study. Patients who already received investigational medicinal product (GZ402...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Received investigational medicinal product (GZ402668 or placebo) in TDU13475 or TDU14981
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Exclusion
Key Trial Info
Start Date :
January 12 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 20 2022
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT02313285
Start Date
January 12 2015
End Date
April 20 2022
Last Update
May 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigational Site Number 276001
Berlin, Germany, 10117